These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35167779)

  • 1. Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.
    Wirta DL; Kuwayama Y; Lu F; Shao H; Odani-Kawabata N
    J Ocul Pharmacol Ther; 2022 Apr; 38(3):240-251. PubMed ID: 35167779
    [No Abstract]   [Full Text] [Related]  

  • 2. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
    Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study.
    Walters TR; Kothe AC; Boyer JL; Usner DW; Lopez K; Duquesroix B; Fechtner RD; Navratil T
    J Glaucoma; 2022 Jun; 31(6):382-391. PubMed ID: 35394456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
    Ge J; Li X; Sun X; He X; Zhang H
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
    Schachar RA; Raber S; Courtney R; Zhang M
    Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension.
    Eveleth D; Starita C; Tressler C
    BMC Ophthalmol; 2012 May; 12():9. PubMed ID: 22607109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.
    Walters TR; Ahmed IIK; Lewis RA; Usner DW; Lopez J; Kopczynski CC; Heah T;
    Ophthalmol Glaucoma; 2019; 2(5):280-289. PubMed ID: 32672669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
    Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
    Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
    Parrish RK; Palmberg P; Sheu WP;
    Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
    Stalmans I; Lim KS; Oddone F; Fichtl M; Belda JI; Hommer A; Laganovska G; Schweitzer C; Voykov B; Zarnowski T; Holló G
    Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):179-190. PubMed ID: 37615697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure.
    Denis P; Baudouin C; Bron A; Nordmann JP; Renard JP; Rouland JF; Sellem E; Amrane M
    BMC Ophthalmol; 2010 Feb; 10():4. PubMed ID: 20181282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
    Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
    Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
    Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA;
    Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
    Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
    Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
    Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM;
    Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
    DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
    Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
    Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM
    Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA; Cimino L
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.